,7 A retrospective case series reported that in giant cell arteritis, baricitinib and tofacitinib reduced inflammatory markers (C-reactive protein and erythrocyte sedimentation rate) and corticosteroid use without relapses.6 This evidence concerns the gene CRP and temporal arteritis.